The efficacy and safety of C1-INH(SC) in patients with HAE have been demonstrated in an open-label extension (OLE) of the pivotal phase III (COMPACT) study of C1-INH(SC) [22]. The gene discussed is SERPING1; the disease is hereditary angioedema.